We would love to hear your thoughts about our site and services, please take our survey here.
I don't believe there was a leak. The data behind yesterday's RNS was published on July 25th, indeed Sayj posted the excerpt that day.
All joking aside, does anyone have a strong view on these trades? I'd love to say they are buys but unclear brokers could have bought enough sub 110 to fill a 110 order?
Yes, the simply wall street number is incorrect and should be ignored. Per Berenberg's research published last week the company had £33m of cash 1 month ago. As Phantom points out, there are multiple other assets most notably IP which is not taken into account in sws most basic of calculations.
As i understand it, the supply of reagents (the cause of the delay) was coming from a longstanding and trusted partner. The capacity to produce and hence supply the reagents to Angle was unexpectedly sequestered by someone higher up the food chain (the same partner producing (different) reagents used in PCR tests - global pandemic unsurprisingly taking precedence), thus resulting in a delay of supply to Angle. Changing to a different supplier is a very timely process and would not have altered the problem. Not incompetence on the company's behalf imo.
I'm also surprised there has been no director buying with a halving in the share price. Don't want to or not allowed to?
Agreed. Further NTCD-M3 studies with results due Q1 and presumably (hopefully) a partnering deal to follow shortly thereafter. Not surprised potential partners on XF-73 require greater clarity on design of Phase 3 before partnering discussion can progress to next stage (but good to have expectations managed appropriately). Given the SP has more than halved since the intra-day peak following phase 2 results on XF-73 last year, I continue to believe there is tremendous upside potential with several catalysts over the next 3-12 months.
Jelenko, great colour. May I ask, did this come from the company? (I asked a similar question of them yesterday but have yet to hear back).
Thanks for flagging Arsenal. I thought the language and tone from Neil in last night's presentation was more upbeat and confident than i had heard this year. Noteworthy comments on his recent trip to the US to meet "operational connections, banks and potential investors". I also thought the tone around Spor-Cov had advanced a little as we would hope - "watch out for news". For a company with 2x assets going into P3, the valuation strikes me as very conservative and i hope Neil's marketing trips (another one planned for January around JPM conference I believe) will get the message across to a different (and receptive) audience. I bought a little more this morning.
I think these appointments represent a fairly natural progression for a company approaching a period of significant growth (and doesn't ring the imminent fund raise bell - having raised funds in June) . To the extent the company does indeed have Nasdaq aspirations the previous joint brokers were not the most appropriate partners and someone like Jefferies with a strong US equity presence is a must.
Comprehensive initiation from Trinity published today - 255p target with "further upside as value inflection points, notably FDA approval and further pharma services contracts, are reached".
https://www.trinitydelta.org/wp-content/uploads/2021/05/AGL-Initiation-210511.pdf